Capecitabine, oxaliplatin and irinotecan (COI regimen) as perioperative treatment of resectable gastric or gastroesophageal junction (GEJ) cancer

被引：0
|
作者：
Berenato, R. [1 ]
Pietrantonio, F. [1 ]
Niger, M. [1 ]
Caporale, M. [1 ]
Ricchini, F. [1 ]
Maggi, C. [1 ]
Bossi, I. [1 ]
Consonni, P. V. [1 ]
de Braud, F. [1 ]
Di Bartolomeo, M. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
L13
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [1] Capecitabine, oxaliplatin and irinotecan (COI regimen) as perioperative treatment of resectable gastric or gastroesophafageal junction (GEJ) cancer
    Berenato, R.
    Pellegrinelli, A.
    Pietrantonio, F.
    Niger, M.
    Caporale, M.
    De Braud, F.
    Ricchini, F.
    Maggi, C.
    Di Bartolomeo, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S421 - S421
  • [2] Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma
    Fritsch, Ralph
    Hoeppner, Jens
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (04) : 285 - 291
  • [3] COI regimen (capecitabine, oxaliplatin, irinotecan) as possible neoadjuvant treatment in metastatic colorectal cancer patients
    Buzzoni, R.
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Gevorgyan, A.
    Dotti, K. F.
    Mancin, M.
    Platania, M.
    Colombo, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI39 - XI39
  • [4] Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions
    Berenato, Rosa
    Morano, Federica
    Pietrantonio, Filippo
    Cotsoglou, Christian
    Caporale, Marta
    Infante, Gabriele
    Pellegrinelli, Alessandro
    Alessi, Alessandra
    Battiston, Carlo
    Coppa, Jorgelina
    Padovano, Barbara
    Mennitto, Alessia
    Niger, Monica
    Fuca, Giovanni
    Lazzati, Silvia
    Greco, Giorgio
    Delconte, Gabriele
    de Braud, Filippo
    Mazzaferro, Vincenzo
    Di Bartolomeo, Maria
    [J]. ONCOLOGY, 2017, 93 (05) : 279 - 286
  • [5] Perioperative capecitabine-oxaliplatin chemotherapy in resectable gastric cancer
    Arab, A.
    Belhadef, S.
    Benamor, B.
    Mesrour, I.
    Mechta, K.
    Megari, H.
    Hammouda, D.
    Kheloufi, M.
    Rebaine, M.
    Mahfouf, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S142 - S142
  • [6] Toripalimab combined with fluorouracil, leucovorin calcium, oxaliplatin and irinotecan (FOLFIRINOX) regimen or combined with oxaliplatin and tegafur (SOX) regimen in perioperative treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma (G/GEJ): An open-label, randomized, phase II study
    Liu, Rui
    Ji, Zhi
    Wang, Xia
    Zhang, Le
    Yang, Yuchong
    Ning, Tao
    Ge, Shaohua
    Li, Hongli
    Bai, Ming
    Deng, Ting
    Ba, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Docetaxel, oxaliplatin, and capecitabine (DOX) combination chemotherapy for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Di Lauro, Luigi
    Sergi, Domenico
    Belli, Franca
    Fattoruso, Silvia Ileana
    Arena, Maria Grazia
    Pizzuti, Laura
    Vici, Patrizia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Phase I/II study of capecitabine, oxaliplatin, irinotecan and cetuximab (COI-E regimen) as perioperative treatment of high-risk or borderline resectable colorectal cancer liver metastases (CLM)
    Pietrantonio, F.
    Coppa, J.
    De Braud, F.
    Mazzaferro, V.
    Biondani, P.
    Perrone, F.
    Gevorgyan, A.
    Dotti, K. F.
    Cotsoglou, C.
    Di Bartolomeo, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S504 - S504
  • [9] A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer
    El-Rayes, B. F.
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Heilbrun, L. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur Gregory Ang
    Mulder, Karen E.
    Brezden-Masley, Christine
    Vickers, Michael M.
    Monzon, Jose Gerard
    Kennecke, Hagen F.
    Goel, Rakesh
    Ghosh, Sunita
    Marginean, Horia
    Vos, Larissa Joy
    Raynard, SeeSee Juliana
    Young, Kristine Lee
    Fields, Anthony L. A.
    Maroun, Jean Alfred
    Spratlin, Jennifer L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345